. 2021 Sep 1;38(5):287–295. doi: 10.5152/balkanmedj.2021.20086
Content of this journal is licensed under a Table 4.
EGFR, ALK, ROS, and PD-L1 Positivity Rate According to Histological Subgroups
| No. EGFR Positivity (%) | No. ALK Positivity (%) | No. ROS1 Positivity (%) | No. PD-L1 Positivity (%) | |
|---|---|---|---|---|
| Adenocarcinoma | 8 (8.1%) | 7 (6.7%) | 2 (2.2%) | 70 (48.3%) |
| Squamous cell carcinoma | 0 (0.0%) | 1 (7.7%) | 0 (0.0%) | 25 (64.1%) |
| NSCLC-NOS | 1 (8.3%) | 3 (27.3%) | 0 (0.0%) | 9 (40.9%) |
| Pleomorphic carcinoma | 0 (0.0%) | 0 (0.0%) | 0 (0.0%) | 1 (100%) |
| Other carcinoma | 0 (0.0%) | 0 (0.0%) | 0 (0.0%) | 0 (0.0%) |
EGFR, epidermal growth factor receptor; ALK, anaplastic lymphoma tyrosine kinase gene; ROS1, proto-oncogene tyrosine-protein kinase 1 ROS; PD-L1, programmed cell death protein ligand-1; NSCLC-NOS, non-small lung cancer-not otherwise specified.